KORU Medical Posts 22% Revenue Growth to $41.1M, International Sales +71%
KORU Medical Systems delivered full-year revenue growth of 22% to $41.1 million, with international core sales up 71% and EU MDR certification for its Freedom 60 device. PST business fell 30% on contract timing, gross margin slipped 30 basis points, and a CEO transition was announced with 2026 guidance initiated.
1. Full-Year Financial Performance
KORU Medical delivered full-year revenue of $41.1 million, a 22% increase, with positive operating cash flow and ending cash of $8.9 million. The company reported a quarterly loss of $0.01 per share, beating the prior year’s $0.03 loss and generating positive adjusted EBITDA.
2. European Market Certification and International Growth
The company secured EU MDR certification for its Freedom 60 pump with prefilled syringe compatibility, targeting a $50 million addressable market in Europe. International core business surged 71% year-over-year, driven by new patient starts and market share expansion from 10% to 20%.
3. Profitability and Segment Variances
Gross margin declined by 30 basis points in Q4 due to higher material costs and tariffs, while the PST segment revenue dipped 30% following contract milestone timing. Two new pharma collaborations were initiated to expand KORU’s development pipeline into additional therapeutic areas.
4. CEO Transition and 2026 Guidance
A leadership change was announced, with a new CEO set to assume the role ahead of full-year 2026 guidance initiation. Management expects steady US growth, a step-up in international prefill conversions in the second half of 2026, and entry into new geographies each quarter.